Clinical Trials Logo

Clinical Trial Summary

Background: Functional hypothalamic amenorrhea (functional HA) is a condition where a woman s period stops for a temporary time. This is due to improper function of the hypothalamus. This is the part of the brain that directs the whole reproductive system. Researchers want to learn more about functional HA. They also want to learn how diet, exercise, and other factors may change women s menstrual cycles. Objective: To better understand functional HA. Eligibility: Healthy women ages 18-28 years old who: - Have regular periods - Exercise no more than 4 hours a week - Had their first period at age 11-14 Design: Participants will be prescreened over the phone. Participants will be screened with: - Blood and urine tests - Medical history - Physical exam. Participants will have 9 or 10 visits over about 3 menstrual cycles. These include: - Repeat of screening tests - Questionnaires - Exercise test - Resting energy expenditure test: Participants fast overnight before the test. They lie on their back under a canopy for a half hour. - Body composition test: This is done with a dual energy x-ray absorptiometry (DXA) scan. - Pelvic ultrasound - For two full-day visits, an IV is inserted into an arm vein. The IV takes a blood sample every 10 minutes for 8 hours. Participants will keep logs: - Menstrual cycle log - Diet log for three 4-day cycles Participants will receive test kits to complete at home: - Daily blood and urine sample - Ovulation Participants will take a daily iron supplement. They will wear a wristband that monitors activity 24 hours a day. Participants will stick to a special diet for two 5-day periods of time. They will complete two 4-day exercise programs....


Clinical Trial Description

Functional hypothalamic amenorrhea (HA) is a reversible form of hypogonadotropic hypogonadism (HH) that can be triggered by stressors such as exercise, nutritional deficits, and psychological stress. Dysfunction of the hypothalamic component of the reproductive axis plays a key role in functional HA and is manifest by an altered pattern of luteinizing hormone (LH) pulses detectable in peripheral blood. There is ample evidence supporting the use of LH as a surrogate marker of hypothalamic gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus. There is also significant evidence that women vary in their susceptibility to such stress-induced amenorrhea, pointing to a role for both environmental and genetic factors in the etiology of functional HA. However, the variation in changes in GnRH pulse frequency in response to stressors in healthy women has not been defined. Data from previous work in our lab has suggested that rare variants in genes associated with other forms of HH may also contribute to the variability seen in susceptibility to functional HA. The long-term goal of our research is to examine the interaction of environment and genes in HA. In this pilot study we propose to examine the inter-individual variability in pulsatile LH secretion in response to standardized neutral and deficient energy availability (NEA and DEA, respectively) in normal women. We will then relate this primary end-point to proposed predictive factors including past reproductive and family history and markers of current metabolic status and their response to energy availability. Our initial analyses will help to determine simplified biomarkers that can be translated to larger studies examining the potential combined effect of energy availability and genotype. The proposed pilot study is a single-site, 2-period study in healthy female volunteers. The study will enroll approximately 300 participants with a target for study completion of 36 subjects. Eligible participants will be females greater than or equal to 18 years of age. Eligible participants will have had menarche at or before 14 years of age and no earlier than age 11. Eligible participants will have a gynecological age (years after menarche) of 14 years or less. The upper age limit will vary based on each subject s age of menarche and fall between 25 and 28 among participants. Eligible participants will confirm at the pre-screening call having normal menstrual cycles (self-reported) for at least the previous 2 months and ovulation will be confirmed during the menstrual cycle before the start of intervention. The primary outcome will be changes in daytime LH pulse frequency, when comparing NEA vs DEA. Secondary measures will evaluate past reproductive history, family history, and current metabolic status using medical history interviews, lifestyle questionnaires and maximum oxygen uptake (as a measure of fitness). Resting energy expenditure, body composition as well as metabolic and stress hormones will be measured at baseline and in association with the interventions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02858336
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date January 12, 2017
Completion date June 29, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05022992 - Effects of a Single Bout of Resistance Training Session on Hormonal Response in Pre-pubertal and Pubertal Boys N/A
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04862208 - Breakfast Consumption and Energy Balance in Active Adult Males N/A
Recruiting NCT01121783 - The Effect of Lactisole on the Responses to Glucose Solution N/A
Completed NCT03677336 - Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI Phase 4
Completed NCT04414488 - The Impact of Regional Anaesthesia on Hormone Levels in Thoracic Surgery.
Completed NCT04930224 - Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients
Completed NCT00342498 - Estrogen Receptor Gene Mutations N/A
Completed NCT05136742 - Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes N/A
Recruiting NCT04326374 - Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency Phase 3
Completed NCT02781727 - A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Phase 3
Active, not recruiting NCT05288166 - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) Phase 3